CliffBio
small molecule

FARESTON

TOREMIFENE CITRATE

Loss of exclusivity—loss of exclusivity
CompanyKyowa Kirin Co. →See this company's full patent-cliff portfolio

Drug detail

Brand nameFARESTON
Active ingredientTOREMIFENE CITRATE
StrengthEQ 60MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 1997
Marketing statusDISCN

More from Kyowa Kirin Co.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FARESTON patent cliff — loss of exclusivity — | CliffBio